HAE

Over the past six months, Haemonetics' share price has outperformed the S&P500 Index by +12.18%, but as of May 7, 2026, shares were trading -6.27% below their 200-day moving average. On May 7, 2026, Haemonetics reported its fourth-quarter and fiscal year 2026 financial results, surpassing analyst expectations, which led to the stock trading up 11.8% during mid-day trading. On March 11, 2026, Citigroup cut its price target on Haemonetics from $75.00 to $70.00 and maintained a "neutral" rating. On April 13, 2026, Mizuho cut its price target on Haemonetics from $80.00 to $70.00 but maintained an "outperform" rating. On February 6, 2026, Robert W. Baird set an $81.00 price target, and BTIG Research reiterated a "buy" rating with an $88.00 price target. On January 10, 2026, Wall Street Zen upgraded Haemonetics from a "hold" to a "buy" rating. In December 2023, the acquisition of OpSens Inc. added the Sensor-Guided Technologies product line to Haemonetics' portfolio.